SWOG clinical trial number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer

Open
Phase
III
Abbreviated Title
Ph III Evaluation of De-escalation of Radiation for Stage I, Hormone Sensitive HER2-, Treatment of Stage I, Hormone Sensitive, HER2- Oncotype Recurrence Score </=18
Status Notes
CTSU/NRG-BR007 has been endorsed and activated by SWOG, effective 6/15/2021. CTSU/NRG-BR007 was activated by NRG Oncology, effective 6/7/21.
Activated
06/07/2021

Research committees

Breast Cancer

Eligibility Criteria Expand/Collapse

Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org).